Pharvaris (PHVS) Competitors $22.30 -0.69 (-3.00%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$22.25 -0.05 (-0.22%) As of 08/15/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHVS vs. ACAD, CYTK, AKRO, KRYS, ADMA, AAPG, LNTH, ACLX, ZLAB, and PCVXShould you be buying Pharvaris stock or one of its competitors? The main competitors of Pharvaris include ACADIA Pharmaceuticals (ACAD), Cytokinetics (CYTK), Akero Therapeutics (AKRO), Krystal Biotech (KRYS), ADMA Biologics (ADMA), Ascentage Pharma Group International (AAPG), Lantheus (LNTH), Arcellx (ACLX), Zai Lab (ZLAB), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry. Pharvaris vs. Its Competitors ACADIA Pharmaceuticals Cytokinetics Akero Therapeutics Krystal Biotech ADMA Biologics Ascentage Pharma Group International Lantheus Arcellx Zai Lab Vaxcyte ACADIA Pharmaceuticals (NASDAQ:ACAD) and Pharvaris (NASDAQ:PHVS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk. Does the media prefer ACAD or PHVS? In the previous week, ACADIA Pharmaceuticals had 5 more articles in the media than Pharvaris. MarketBeat recorded 24 mentions for ACADIA Pharmaceuticals and 19 mentions for Pharvaris. ACADIA Pharmaceuticals' average media sentiment score of 0.77 beat Pharvaris' score of 0.29 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 8 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pharvaris 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is ACAD or PHVS more profitable? ACADIA Pharmaceuticals has a net margin of 21.80% compared to Pharvaris' net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 14.69% beat Pharvaris' return on equity.Company Net Margins Return on Equity Return on Assets ACADIA Pharmaceuticals21.80% 14.69% 9.41% Pharvaris N/A -69.09%-63.34% Which has more risk & volatility, ACAD or PHVS? ACADIA Pharmaceuticals has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, Pharvaris has a beta of -2.81, meaning that its share price is 381% less volatile than the S&P 500. Do institutionals and insiders hold more shares of ACAD or PHVS? 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 26.5% of ACADIA Pharmaceuticals shares are held by company insiders. Comparatively, 11.8% of Pharvaris shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has better valuation & earnings, ACAD or PHVS? ACADIA Pharmaceuticals has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioACADIA Pharmaceuticals$1.02B4.19$226.45M$1.3319.05PharvarisN/AN/A-$145.24M-$3.36-6.64 Do analysts recommend ACAD or PHVS? ACADIA Pharmaceuticals currently has a consensus target price of $28.88, suggesting a potential upside of 14.00%. Pharvaris has a consensus target price of $35.60, suggesting a potential upside of 59.64%. Given Pharvaris' stronger consensus rating and higher possible upside, analysts plainly believe Pharvaris is more favorable than ACADIA Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ACADIA Pharmaceuticals 1 Sell rating(s) 6 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.61Pharvaris 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryACADIA Pharmaceuticals beats Pharvaris on 14 of the 16 factors compared between the two stocks. Get Pharvaris News Delivered to You Automatically Sign up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PHVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHVS vs. The Competition Export to ExcelMetricPharvarisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.20B$3.10B$5.68B$9.81BDividend YieldN/A2.23%3.79%4.11%P/E Ratio-6.6420.8931.0825.11Price / SalesN/A364.47466.21115.16Price / CashN/A42.3037.4059.05Price / Book5.588.659.096.18Net Income-$145.24M-$54.65M$3.26B$265.11M7 Day Performance10.83%6.56%7.36%4.21%1 Month Performance-3.04%7.53%5.47%2.01%1 Year Performance18.93%13.69%30.61%23.74% Pharvaris Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHVSPharvaris2.4403 of 5 stars$22.30-3.0%$35.60+59.6%+16.2%$1.20BN/A-6.6430News CoverageEarnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionACADACADIA Pharmaceuticals3.9071 of 5 stars$24.82+0.9%$28.88+16.3%+64.5%$4.15B$957.80M18.66510News CoverageAnalyst UpgradeCYTKCytokinetics3.6857 of 5 stars$33.23-2.6%$70.69+112.7%-32.2%$4.08B$18.47M-6.52250News CoverageAnalyst RevisionAKROAkero Therapeutics3.9498 of 5 stars$48.28-4.3%$81.57+69.0%+103.0%$4.02BN/A-24.1430Trending NewsEarnings ReportAnalyst UpgradeInsider TradeAnalyst RevisionKRYSKrystal Biotech4.5729 of 5 stars$137.54-0.8%$210.75+53.2%-22.5%$4.01B$290.52M27.96210ADMAADMA Biologics4.3987 of 5 stars$16.40-0.7%$27.67+68.7%-3.4%$3.94B$426.45M19.07530News CoveragePositive NewsAAPGAscentage Pharma Group InternationalN/A$40.04-4.6%N/AN/A$3.90B$134.35M0.00600News CoverageGap UpLNTHLantheus4.7879 of 5 stars$56.07-2.0%$105.50+88.2%-43.0%$3.89B$1.53B14.91700ACLXArcellx1.8481 of 5 stars$69.10-2.0%$114.31+65.4%+14.2%$3.89B$107.94M-20.2080ZLABZai Lab2.4213 of 5 stars$34.66-0.9%$57.22+65.1%+114.6%$3.88B$398.99M-16.991,869News CoverageInsider TradePCVXVaxcyte2.1403 of 5 stars$29.67-0.8%$136.50+360.1%-58.3%$3.88BN/A-7.22160News Coverage Related Companies and Tools Related Companies ACADIA Pharmaceuticals Alternatives Cytokinetics Alternatives Akero Therapeutics Alternatives Krystal Biotech Alternatives ADMA Biologics Alternatives Ascentage Pharma Group International Alternatives Lantheus Alternatives Arcellx Alternatives Zai Lab Alternatives Vaxcyte Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHVS) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredNew Federal Land Rush About to Start?A $100 Trillion Wealth Shift Is Already Underway Lithium. Oil. Gold. Trillions in U.S. resources are being ...Stansberry Research | SponsoredThe Debt Crisis Is Coming—Will You Be Ready?A full-blown "economic heart attack" is coming—and the markets aren't ready. The problem? Exploding U.S. de...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Altcoin That Could be Poised to Benefit Most from Trump’s ReturnWith Trump back in office, the crypto tide is turning fast. Regulation is easing. Momentum is building. And ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharvaris N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharvaris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access